This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doherty, T. M. Articles by Andersen, P. Search for Related Content PubMed PubMed Citation Articles by Doherty, T. M. Articles by Andersen, P.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, October 2005, p. 687-702, Vol. 18, No. 4
0893-8512/05/$08.00+0     doi:10.1128/CMR.18.4.687-702.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Vaccines for Tuberculosis: Novel Concepts and Recent Progress

Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark

Three-quarters of a century after the introduction of Mycobacterium bovis BCG, the first tuberculosis vaccine, new vaccines for tuberculosis are finally entering clinical trials. This breakthrough is based not only on advances in proteomics and genomics which have made the construction of new vaccines possible, but also on a greatly expanded knowledge of the immunology of tuberculosis. Here we review our current understanding of how Mycobacterium tuberculosis subverts or survives the host's immune response to cause disease and why the current vaccination strategy, which relies on BCG, is only partially successful in countering the pathogen. This provides a background for describing the new generation of vaccines designed to supplement or replace the current vaccine and the different approaches they take to stimulate immunity against M. tuberculosis.

This article has been cited by other articles:

• Wedlock, D. N., Denis, M., Painter, G. F., Ainge, G. D., Vordermeier, H. M., Hewinson, R. G., Buddle, B. M. (2008). Enhanced Protection against Bovine Tuberculosis after Coadministration of Mycobacterium bovis BCG with a Mycobacterial Protein Vaccine-Adjuvant Combination but Not after Coadministration of Adjuvant Alone. CVI 15: 765-772 [Abstract] [Full Text]  
• Geluk, A., Lin, M. Y., van Meijgaarden, K. E., Leyten, E. M. S., Franken, K. L. M. C., Ottenhoff, T. H. M., Klein, M. R. (2007). T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination. Infect. Immun. 75: 2914-2921 [Abstract] [Full Text]  
• Maglione, P. J., Xu, J., Chan, J. (2007). B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment upon Pulmonary Challenge with Mycobacterium tuberculosis. J. Immunol. 178: 7222-7234 [Abstract] [Full Text]  
• Mathema, B., Kurepina, N. E., Bifani, P. J., Kreiswirth, B. N. (2006). Molecular Epidemiology of Tuberculosis: Current Insights. Clin. Microbiol. Rev. 19: 658-685 [Abstract] [Full Text]  
• O'Riordan, K., Sharlin, D. S., Gross, J., Chang, S., Errabelli, D., Akilov, O. E., Kosaka, S., Nau, G. J., Hasan, T. (2006). Photoinactivation of Mycobacteria In Vitro and in a New Murine Model of Localized Mycobacterium bovis BCG-Induced Granulomatous Infection.. Antimicrob. Agents Chemother. 50: 1828-1834 [Abstract] [Full Text]